Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 5.
doi: 10.1038/s41380-025-03195-7. Online ahead of print.

The role of low subcortical iron, white matter myelin, and oligodendrocytes in schizophrenia: a quantitative susceptibility mapping and diffusion tensor imaging study

Affiliations

The role of low subcortical iron, white matter myelin, and oligodendrocytes in schizophrenia: a quantitative susceptibility mapping and diffusion tensor imaging study

Luke J Vano et al. Mol Psychiatry. .

Abstract

Iron-the most abundant magnetic brain substance-is essential for many biological processes, including dopamine and myelin synthesis. Quantitative susceptibility mapping (QSM) MRI has recently linked altered subcortical magnetic susceptibility (χ) to schizophrenia. Since χ is increased by iron and decreased by myelin, abnormal levels of either could underlie these QSM differences. In white matter tracts, magnetic susceptibility anisotropy (δχ) serves as a myelin-specific marker that is insensitive to iron content. To clarify the origin of case-control χ differences, we employed QSM in 85 individuals with schizophrenia, from first-episode mental health teams, and 86 healthy controls. A subset also underwent diffusion tensor imaging (DTI) to calculate subcortical tissue mean diffusivity, which inversely correlates with myelin concentration and fractional anisotropy. White matter δχ was calculated by combining QSM and DTI. Schizophrenia was associated with lower subcortical χ (d = -0.36, p = 0.023). This was significant in the caudate nucleus (d = -0.37, p = 0.037), putamen (d = -0.36, p = 0.037), globus pallidus (d = -0.57, p = 0.001), and SN-VTA (as previously reported). Additionally, schizophrenia was linked to higher subcortical mean diffusivity (d = 0.44, p = 0.018), and lower white matter δχ (d = -0.37, p = 0.047). These findings suggest that both subcortical iron and brain myelin levels are lower in schizophrenia. By comparing our voxelwise χ maps with postmortem gene expression data, we reveal that regions with lower subcortical χ in schizophrenia are enriched for oligodendrocyte-related genes (p < 0.001). As oligodendrocytes are both the most iron-rich brain cells and essential for myelin synthesis, our results implicate oligodendrocyte dysfunction in schizophrenia pathophysiology.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The views expressed are those of the author(s) and not necessarily those of the NIHR, Department of Health, or Sumitomo Pharma America, Inc. Dr. McCutcheon has received speaker/consultancy fees from Karuna, Janssen, Boehringer Ingelheim, and Otsuka, and co-directs a company that designs digital resources to support treatment of mental illness. Dr. Rutigliano is supported by the EU Horizon 2020 Research and Innovation Program under Marie Skłodowska-Curie grant agreement 101026235 and by Guarantors of Brain with a Post-Doctoral Clinical Fellowship, and has been a consultant for Sumitomo Pharma. Dr. Howes has received investigator-initiated research funding from and/or participated in advisory/speaker meetings organized by Angellini, Autifony, Biogen, Boehringer-Ingelheim, Eli Lilly, Elysium, Heptares, Global Medical Education, Invicro, Jansenn, Karuna, Lundbeck, Merck, Neurocrine, Ontrack/Pangea, Otsuka, Sunovion, Recordati, Roche, Rovi and Viatris/Mylan. He was previously a part-time employee of Lundbeck A/v. Dr Howes has a patent for the use of dopaminergic imaging. All other authors report no biomedical financial interests or potential conflicts of interest. Ethics approval and consent to participate: The Office for Research Ethics Northern Ireland approved data collection for people with schizophrenia as part of a clinical study (19/NI/0098; NCT04038957), and the London Dulwich Research Ethics Committee approved data collection for healthy controls (21/LO/0312). This paper only presents baseline data. Written informed consent was obtained from all participants, and recruitment and study procedures were approved by the institutional review boards at each participating site. Consent for publication: One participant provided potentially identifiable images and gave written informed consent for their publication in this article.

References

    1. McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia—an overview. JAMA Psychiatry. 2020;77:201–10. - PubMed - DOI
    1. Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry. 2012;69:776–86. - PubMed - PMC - DOI
    1. Valdés-Tovar M, Rodríguez-Ramírez AM, Rodríguez-Cárdenas L, Sotelo-Ramírez CE, Camarena B, Sanabrais-Jiménez MA, et al. Insights into myelin dysfunction in schizophrenia and bipolar disorder. World J Psychiatry. 2022;12:264–85. - PubMed - PMC - DOI
    1. Zucca FA, Segura-Aguilar J, Ferrari E, Muñoz P, Paris I, Sulzer D, et al. Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson’s disease. Progress in Neurobiology. 2017;155:96–119. - PubMed - DOI
    1. Saghazadeh A, Mahmoudi M, Shahrokhi S, Mojarrad M, Dastmardi M, Mirbeyk M, et al. Trace elements in schizophrenia: a systematic review and meta-analysis of 39 studies (N = 5151 participants). Nutrition Reviews. 2020;78:278–303. - PubMed - DOI

LinkOut - more resources